Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781
- 1 March 2003
- journal article
- basic science
- Published by Wolters Kluwer Health in AIDS
- Vol. 17 (5) , 653-661
- https://doi.org/10.1097/00002030-200303280-00002
Abstract
Objective: To determine the efficacy of UC781 in preventing HIV-1 transmission through cervical tissue. Design: Use of human cervical tissue organ culture, in which the cervix is in the upper chamber of a transwell and transmission of infective virus is quantified in the lower chamber. Methods: Five-millimeter pieces of cervical tissues are exposed to UC781. After thorough removal of the drug, the tissues are exposed to high doses of cell-free or cell-associated HIV-1. Transmission of HIV-1 through the cervix is measured by determining infection of target cells in the lower chamber. Results: Exposure of cervix to 0.5 μM UC781 for 30 min, followed by extensive washing away of the residual drug, resulted in 95% reduction of subsequent viral transmission. Exposure of the cervix to 1 μM UC781 for 20 min, or 10 μM UC781 for 2 min, resulted in neutralization of T- and M-tropic HIV-1 isolates of various clades, and prevention of cell-associated HIV-1 transmission. Moreover, a 20 min incubation with 10 μM UC781 abolished HIV-1 transmission through the cervix for 48 h after drug pretreatment. Importantly, UC781 was not toxic, even when the cervical tissues were exposed to 20 μM UC781 for 24 h. UC781 was effective against transmission of both cell-free and cell-associated HIV-1 also when formulated into a non-spermicidal (Replen) or spermicidal (BufferGel) gel. Conclusions: Exposure of the cervix to UC781 results in blocking of subsequent HIV-1 transmission with no toxicity. Therefore, UC781 is an excellent candidate microbiocide.Keywords
This publication has 32 references indexed in Scilit:
- Attenuated Infectivity of HIV Type 1 from Epithelial Cells Pretreated with a Tight-Binding Nonnucleoside Reverse Transcriptase InhibitorAIDS Research and Human Retroviruses, 2002
- Science, medicine, and the future: Microbicides in HIV preventionBMJ, 2001
- Safety and Tolerability of BufferGel, a Novel Vaginal Microbicide, in Women in the United StatesClinical Infectious Diseases, 2001
- Topical MicrobicidesSexually Transmitted Diseases, 1998
- Quantification of HIV in semenAIDS, 1997
- Efficacy, Pharmacokinetics, andin VivoAntiviral Activity of UC781, a Highly Potent, Orally Bioavailable Nonnucleoside Reverse Transcriptase Inhibitor of HIV Type 1AIDS Research and Human Retroviruses, 1997
- The Thiocarboxanilide Nonnucleoside UC781 Is a Tight-Binding Inhibitor of HIV-1 Reverse TranscriptaseBiochemistry, 1997
- Development of Vaginal Microbicides for the Prevention of Heterosexual Transmission of HIVJAIDS Journal of Acquired Immune Deficiency Syndromes, 1996
- Detection and biologic characterization of infectious HIV-1 in semen of seropositive menAIDS, 1994
- Reverse Transcription Takes Place within Extracellular HIV-1 Virions: Potential Biological SignificanceAIDS Research and Human Retroviruses, 1993